Article info

Download PDFPDF
Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Authors

  1. Correspondence to Steffen Böhm, Medical Oncology, Barts Health NHS Trust, London EC1A 7BE, UK; bohm.st{at}hotmail.com
View Full Text

Citation

Böhm S, Le N, Lockley M, et al
Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Publication history

  • Received October 16, 2018
  • Revision received November 30, 2018
  • Accepted December 2, 2018
  • First published January 25, 2019.
Online issue publication 
February 04, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.